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Abstract Aims To assess the relationship between genetic polymorphisms and indinavir
pharmacokinetic variability and to study the link between concentrations and short-term
response or metabolic safety. Methods Forty protease inhibitor naive-patients initiating in-
dinavir/ritonavir containing HAART and enrolled in the COPHAR 2 - ANRS 111 trial
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2were studied. At week 2, 4 blood samples were taken before and up to 6 hours follow-
ing drug intake. A population pharmacokinetic analysis was performed using the Stochastic
Approximation Expectation Maximization (SAEM) algorithm implemented in the MONO-
LIX software. Indinavir area under the concentration-time curve (AUC), maximal (Cmax)
and trough concentrations (Ctrough) were derived from the population model and tested for
correlation with short-term viral response and safety measurements, while ritonavir AUC,
Cmax and Ctrough were tested for correlation with short-term biochemical safety. Results A
one-compartment model with first-order absorption and elimination best described both in-
dinavir and ritonavir concentrations. For indinavir, the estimated clearance and volume of
distribution were 22.2 L/h and 97.3 L respectively. The eight patients *1B/*1B for CYP3A4
gene had an absorption decreased by 70% compared to *1A/*1B or *1A/*1A genotypes
(0.5 versus 2.1, P=0.04, likelihood ratio test by permutation). Indinavir AUC and Ctrough
were positively correlated with the HIV RNA decrease between week 0 and week 2 (r=-0.4,
P = 0.03 and r=-0.4, P = 0.03, respectively). Patients with the *1B/*1B genotype had sig-
nificantly lower indinavir Cmax (median 3.6 [range 2.1 - 5.2] ng/mL versus 4.4 [2.2 - 8.3]
ng/mL, P=0.04) and a lower triglycerides increase during the first 4 weeks of treatment (0.1
[-0.7 - 1.4] versus 0.6 [-0.5 - 1.7] mmol/L, P = 0.02). For ritonavir, the estimated clearance
and volume of distribution were 8.3 L/h and 60.7 L respectively and concentrations were
not found to be correlated to biochemical safety. Indinavir and ritonavir absorption rate con-
stants were found to be correlated, as well as their apparent volumes of distribution and
clearances indicating correlated bioavailability of the two drugs. Conclusion CYP3A4*1B
polymorphism was found to influence the pharmacokinetics of indinavir and in some extent
the biochemical safety of indinavir.
Keywords Pharmacokinetics · Nonlinear Mixed Effects Modeling · Protease inhibitors ·
CYP3A4 · Safety · Efficacy
1 Introduction
Indinavir has been one of the preferred protease inhibitor (PI) included in highly active
antiretroviral therapy (HAART). Nowadays, even if not recommended as initial therapy,
indinavir is still used in patients who initiated their therapy with this PI and kept a viral
load below the limit of quantification with an acceptable safety profile. Further compared
to others PI, indinavir exhibits a high penetration into viral reservoirs such as genital com-
partments and CNS [1]. It was found that the indinavir better distribution is leading to better
outcomes in neurological complications related to HIV [2]. The pharmacokinetics (PK) of
indinavir is characterised by high maximal concentrations leading to potential toxicity, no-
tably nephrolithiasis [3] and low minimum concentrations with respect to the 95% inhibitory
concentration of the virus. These low residual concentrations result from an extended ox-
idative metabolism by the cytochrome P450 (CYP3A) isoenzyme [4].The co-administration
of ritonavir, whose molecular structure leads to CYP3A inhibition, therefore enhances expo-
sure to indinavir [5,6]. As a booster, ritonavir is given at lower dose than for therapeutic use,
but was shown nevertheless to influence metabolic profiles especially with respect to lipids
disorders [7,8].
The large inter-patient and intra-patient variability of indinavir pharmacokinetics is well
referenced [9–11]. Genetic polymorphisms could partly explain this variability, as far as
proteins involved in the metabolism and transport of PI are concerned. Few studies have
investigated the impact on indinavir pharmacokinetics of ABCB1 polymorphisms, a gene
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3coding for P-glycoprotein, and of CYP3A5 and CYP3A4*1B polymorphisms. Solas et al.
[12] have shown that the ABCB1 C3435T genotype affects the absorption constant of indi-
navir whereas Verstuyft et al. [13] have reported an absence of association. Anderson et al.
[14] have observed that CYP3A5 expressors (CYP3A5*1 carriers) have significantly faster
oral clearance than non-expressors. To date no relationship was found between CYP3A4*1B
polymorphism and alterations in CYP3A substrate metabolism, but clinical data have shown
an association between CYP3A*1B polymorphism and disease risk/treatment toxicity [15].
Efficacy [16,17] as well as adverse events [18,3] has been related to indinavir plasma
concentrations. Thus, therapeutic drug-monitoring appears to be a potent tool to achieve un-
detectable HIV-RNA and prevent toxicity for this drug. The COPHAR 2 - ANRS 111 trial
is a multi-centre non-comparative pilot trial of early therapeutic drug-monitoring in HIV-
positive patients naive of protease inhibitor containing highly active antiretroviral treatment
(HAART) [19]. We focused on the PK sub-study from the group of patients receiving in-
dinavir boosted with ritonavir. The aims of this paper were to estimate the population PK
parameters and variability of indinavir and ritonavir in HIV patients, to evaluate the impact
of genetic polymorphisms on indinavir PK and to study the link between indinavir concen-
trations and short-term efficacy and metabolic safety.
2 Methods
2.1 Study
The COPHAR 2 - ANRS 111 study is a multi-centre non-comparative prospective pilot trial
of early-dose adaptation in HIV-positive patients naive of protease inhibitors (PI) starting a
PI containing HAART treatment. The trial started on July 2002 and was completed by the
end of March 2005. The objective was to assess the benefit of pharmacological advice based
on trough plasma concentrations of PI. The study involved three groups treated with indi-
navir, nelfinavir or lopinavir respectively. In the present study we analysed the data obtained
during the first month of treatment in the indinavir group. A similar analysis of the data in
the nelfinavir group was performed by Hirt et al [20,19], details of the study can be found
in that paper.
Patients were required to have a baseline plasma viral load value > 1000 copies/mL,
and to be naı¨ve of treatment with protease inhibitor. Patients initiated a HAART treatment
containing 400, 600 or 800 mg of indinavir b.i.d. associated with ritonavir booster (100 mg
b.i.d.) and two nucleoside analogues. The first dose was left to physicians’ discretion and
no dose adaptation was performed from week 0 (W0) to W4. A detailed pharmacokinetic
study was performed at W2. Adherence was evaluated at W2 by means of a validated auto-
questionnaire [21] and patients were classified as adherent when reporting no shift in their
treatment schedule during the last 4 days and non-adherent otherwise.
Viral load and CD4 count were collected at baseline (D0) and at W2. Biochemical pro-
files of total cholesterol, high density lipoprotein cholesterol, triglyceride and glycaemia as
well as creatinine clearance and clinical events (diarrhoea grade of 2) were collected 4 weeks
before treatment initiation (W-4) and at W4.
The study was performed in accordance with the Declaration of Helsinki and its amend-
ments. All subjects gave written informed consent and the protocol was approved by the
Ethic Committee of the Biceˆtre Hospital (France) as well as the amendment for the pharma-
cogenetic study.
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42.2 Indinavir and ritonavir concentration measurements
During a visit to the hospital at W2, the patients were sampled on arrival to measure trough
concentrations. Patients were asked to record the time at which the dose was taken on the
previous evening. Then they were given their medications, and sampled again 1 h, 3 h and 6
h after drug administration. Plasma concentrations were assumed at steady state with trough
concentrations considered as following the drug intake using the delay reported by the pa-
tient from previous dosing. Plasma concentrations were determined in the laboratories of
the hospitals by specific high-performance liquid chromatography. The participant labora-
tories were cross-validated before starting the study. Results of the blind inter-laboratory
quality control at three concentrations for indinavir and for ritonavir were within 15% of the
target values for medium and high values and within 20% for low values. Lower limits of
quantification (LOQ) were 0.02 mg/L for indinavir and 0.025 mg/L for ritonavir.
2.3 Genetic polymorphisms
All the genotyping analyses were performed in the same laboratory. Total deoxyribonucleic
acid (DNA) was extracted from plasma samples by use of the QIAamp DNA Blood Mini
Kit (Qiagen, Courtaboeuf, France). ABCB1 polymorphisms in exons 21 (GG, GT, TT) and
26 (CC, CT, TT) were determined by use of previously-published methods [22]. Genotyp-
ing of CYP3A5 (*1*1, *1*3, *3*3, *1*6, *6*6) was performed by real-time polymerase
chain reaction by use of TaqMan MGB probe technology (Applied Biosystems). Genotyp-
ing for CYP3A4 (*1B*1B, *1B*1A, *1A*1A) was determined by polymerase chain reaction
(PCR) followed by direct sequencing. PCR was performed by use of a GenAmp PCR Sys-
tem 9700 (Applied Biosystems, Courtaboeuf, France) according to a previously-published
method [23]. Amplified DNA was purified by use of the QiaQuick DNA Purification System
(Qiagen) and sequenced by use of BigDye Terminator chemistry and an ABI PRISM 3100
genetic analyser (Applied Biosystems). For each genotyping analysis, at least 2 positive
controls were used: 1 homozygous for the wild-type allele and 1 heterozygous and, when
available, 1 homozygous for the mutated allele. These controls were DNA that had already
been sequenced.
Allele frequencies (p for the wild allele and q = 1 - p for the mutant allele) were estimated
by gene counting. Departure from Hardy-Weinberg proportions (p2, 2pq, q2) was tested by
a χ2 test with 1 degree of freedom within each ethnic group [24]. We used two approaches
to define patients belonging to an ethnic group: i. classification on the patient town, birth
area and nationality and ii. classification by means of their genotype information using the
Structure software [25]. This software is based on a Bayesian approach and computes a
posteriori probabilities for each individual of belonging to a given ethnic group. We assumed
each locus to be at the Hardy-Weinberg equilibrium and patients to originate in one ethnic
group (with its own characteristic set of allele frequencies).
2.4 Population pharmacokinetic analysis
We used a population approach to analyse the concentration-time data at W2 for indinavir
and for ritonavir separately. Model fitting and estimation of the population model param-
eters were performed by use of the Stochastic Approximation Expectation Maximization
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5algorithm (SAEM) for nonlinear mixed-effects models implemented in the MONOLIX soft-
ware version 2.1 [26–28]. Both indinavir and ritonavir concentrations were fitted by a one-
compartment model with first-order absorption and first-order elimination parameterised in
absorption rate constant (ka), oral clearance (Cl/F) and oral volume of distribution (V/F).
Each model was assumed at steady state with trough concentrations considered as following
the drug intake.
An exponential model was used for inter-individual variability where random effects
were assumed to follow a normal distribution with zero mean and diagonal variance ma-
trix. Additive, proportional and combined error models were tested and model choice was
based on the likelihood ratio test (LRT) and goodness-of-fit plots (observed vs. predicted
population and individual concentrations, population and individual weighted residuals vs.
predicted concentrations and vs. time). We performed a visual predictive check (VPC) with
1000 simulated data sets to evaluate the basic model [29].
Interaction between ritonavir and indinavir pharmacokinetics was evaluated with the
individual parameters estimated from the basic model for each drug. All the different corre-
lations were tested with the Spearman non-parametric correlation test.
2.5 Assessment of the effect of covariates
The effects of the following covariates were evaluated from the basic model: dose, concomi-
tant use of the zidovudine lamivudine combination (AZT/3TC), co-infection by hepatitis C
or B (VHC/VHB), adherence as previously defined, sex, ethnic group, the four studied ge-
netic polymorphisms (ABCB1 exon 26, ABCB1 exon 21, CYP3A5 and CYP3A4) and the
CDC classification for HIV infection as categorical variables, age, body mass index (BMI),
body weight, creatinine clearance, albumin and orosomucoid levels as continous variables.
The latter were centered to the median and log-transformed for model interpretation conve-
nience.
Each of the four genetic polymorphisms was analysed by means of two binary categori-
sations: first, wild homozygotes versus heterozygotes or mutant homozygotes, second, het-
erozygotes or wild homozygotes versus mutant homozygotes. Categorisation in three classes
was also tested: wild homozygotes versus heterozygotes versus mutant homozygotes. Miss-
ing continuous covariates were replaced with the median and patients with missing dicrete
covariates were discarded for the corresponding analysis. The effects of covariates on the
empirical Bayes estimates (EBE) of each individual pharmacokinetic parameters from the
basic model were tested with the Wilcoxon non-parametric test for categorical variables and
the Spearman non-parametric correlation test for continuous variables. The population co-
variate model was built with the covariates which were found to have an effect in this first
step with a P-value < 0.1. When a genetic covariate was found to have an effect whatever
the categorisation, the same categorisation as other genetic covariates also found to have an
effect was chosen in model selection for consistency.
A forward selection of these covariates for the population model was performed by use
of the likelihood ratio test (LRT) with a significance threshold at P < 0.05. From this as-
cending method, a backward elimination procedure was performed. In order to correct the
inflation of the LRT type I error on small sample size [30], the backward selection was
realized using permutation [31]. More specifically, 1000 data sets are generated by permut-
ing the rows of the covariates matrix from the original data set. For each covariate, one
likelihood ratio statistic LRT obs is estimated from the original data and one likelihood ratio
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6statistic LRT perm is estimated from each of the 1000 data sets. Thus, we obtain j=1,...,1000
LRT perm j . The permutation P-value is the proportion : card(LRT perm j > LRT obs)/1000.
2.6 Short-term efficacy and safety and link with concentrations
As there was no change of dose before W4, we studied the link between concentration at
W2 and efficacy or safety during the first two or four weeks of treatment. For short-term
efficacy, the difference of log viral load between the day of treatment initiation and W2
(∆ logV L) was studied. The significance of the viral load decrease was tested by a Wilcoxon
non-parametric paired test.
Individual area under the concentration-time curve (AUC), maximal plasma concentra-
tions (Cmax) and trough concentrations (Ctrough) of indinavir at steady-state were derived for
each patient by use of the EBE of the individual parameters from the basic model and their
corresponding dose of indinavir. The relationship between indinavir dose, indinavir AUC,
Cmax, Ctrough and ∆ logV L was evaluated by use of the Spearman correlation test. A Wilcoxon
non-parametric test was performed to compare ∆ logV L between patients with or without a
Ctrough below the lower limit of the therapeutic range used in the COPHAR 2 - ANRS 111
trial: 150 ng/mL.
Safety was analysed through the difference between 4 weeks before and 4 weeks after
treatment initiation in total cholesterol (∆TC), high density lipoprotein cholesterol (∆HDL),
triglyceride (∆ trig) and glycaemia (∆gly) and also through appearance of diarrhoea (grade
2) between treatment initiation and W4. To our knowledge, no precocious biological markers
exist for nephrolithiasis, however creatinine clearance has been found to relate to occurence
of severe adverse events (including nephrolithiasis) in a multivariate analysis [3]. Thus, we
also analysed the difference in creatinine clearance (∆ClCr), computed with the Cockcroft-
Gault formula using body weigth and serum creatinine 4 weeks before and 4 weeks after
treatment initiation. The significance of these differences was tested by use of a Wilcoxon
non-parametric paired test.
We performed Spearman correlation tests between indinavir dose, indinavir AUC, Cmax,
Ctrough and ∆TC, ∆HDL, ∆ trig, ∆gly and ∆ClCr. We used Wilcoxon non-parametric tests
to compare these differences between patients with or without an indinavir Ctrough over the
upper limit defined in the therapeutic index (550 ng/mL). We studied the link between the
appearance of grade 2 diarrhoea (yes/no) between treatment initiation and W4 and indinavir
dose, indinavir AUC, Cmax, Ctrough using a Wilcoxon non-parametric test and we studied the
association with or without an indinavir Ctrough > 550 ng/mL using a Fisher exact test.
We assessed the relation between the genetic polymorphisms remaining in the final
population model and indinavir dose, indinavir AUC, Cmax, Ctrough and the relation be-
tween these genetic polymorphisms and the short-term efficacy and safety outcomes using
Wilcoxon non-parametric tests.
We also derived AUC, Cmax, Ctrough for ritonavir and performed Spearman correlation
tests with ∆TC, ∆HDL, ∆ trig, ∆gly and ∆ClCr as well as Wilcoxon non-parametric tests
on appearance of grade 2 diarrhoea.
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73 Results
3.1 Patients
Forty-two patients were included in this treatment group of the COPHAR 2 ANRS - 111
trial, one patient withdrew from the study and one switched to another protease inhibitor
during the first week of treatment. We therefore obtained pharmacokinetic data from 40
patients (27 men, 13 women) with a median age of 36.5 years (20.0 - 59.0). Table 1 describes
the main characteristics of the 40 studied patients.
Both approaches to allocate the ethnic group provided corroborating results. Using the
civic information we allocated 20 patients to the African group and 20 to the Caucasian
group. Given that one patient had missing information for all genotypes, the Structure soft-
ware allocated 19 patients to the Caucasian group and 20 to the African group. In the result-
ing two ethnic groups, Hardy-Weinberg proportions were respected for all polymorphisms
under study as shown in Table 2.
3.2 Indinavir pharmacokinetics
For two patients, two samples were missing, the trough and the 6 h concentrations and only
the trough concentration was available for another. Among the 155 samples, two indinavir
plasma concentrations in one patient were below the limit of quantification (at 1 h and at
trough) and were discarded from the analysis. Figure 1a displays indinavir plasma concen-
trations at W2 versus time. It shows that there is a high inter-individual variability.
The best error model was a proportional error model. The population estimates are dis-
played in Table 3. All the relative standard errors (RSE) were below 25% with the exception
of ka and ωV/F (around 30 and 60% respectively). The inter-individual variance of ka in this
study was rather important (above 100%). The simulated median and the 90th interval are
displayed in Figure 2a together with all the observed concentrations of indinavir. This graph
shows good evidence of the adequacy of the model.
From that basic model, we first tested the effects of the covariates on the individual
parameters estimates. Effects of age (P = 0.03) and ABCB1 exon 26 polymorphism (P=0.09)
on Cl/F and of CDC classification (P = 0.09) and CYP3A4*1B polymorphism (P = 0.09)
on ka were found. Both ABCB1 exon 26 and CYP3A4*1B polymorphism variables were
dichotomised in mutant homozygotes versus other genotypes. After the forward selection
based on LRT, the population model had CYP3A4 effect on ka (P = 0.02) and age effect
on Cl/F (P = 0.03). The age effect on clearance was withdrawn from the model after the
backward selection based on permutation test. In the final model, Absorption rate constant
was decreased by 70% (P = 0.04, LRT by permutation) in patients *1B*1B for the CYP3A4
allele:
ka = 2.1×e−1.3×CYP3A4 with
{
CYP3A4=0 for patients CYP3A4*1A*1A or CYP3A4*1A*1B
CYP3A4=1 for patients CYP3A4*1B*1B
The population parameters of this final model and their RSE are given in Table 3 for the
thirty-eight patients with available genotyping for CYP3A4*1B polymorphism. The inter-
individual variability for ka decreased by 27% from the basic model with the incorporation
of the covariate and residual variability was 44.7%.
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Fig. 1 Observed plasma indinavir concentration (a) and plasma ritonavir concentration (b) versus time col-
lected two weeks after treatment initiation, in 40 HIV naive-patients receiving indinavir plus 100 mg of
ritonavir b.i.d. In the indinavir plot the plain lines correspond to an indinavir dose of 400 mg b.i.d., the dashed
lines to 600 mg b.i.d. and the dotted lines to 800 mg b.i.d. Sampling times following drug administration were
measured by the nurse. Concentrations were assumed at steady state, trough concentrations are displayed as
following the drug intake at sampling times deduced from the patient record.
3.3 Ritonavir pharmacokinetics
One patient who had indinavir concentrations had no concentration for ritonavir, so we only
analysed ritonavir data for 39 patients. The same 5 samples for indinavir mentioned in the
preceding paragraph were also missing. Among the 151 samples, two ritonavir plasma con-
centrations at 1 h and at trough in one patient and one concentration at 12 h in another patient
were below the limit of quantification and were discarded. Observed plasma concentrations
are displayed in Figure 1b, and it should be noticed that some patients exhibited high plasma
concentrations (above 2000 ng/mL) for a dose of 100 mg b.i.d.
A proportional error model was selected. The population estimates are displayed in Ta-
ble 4. All the RSE were below 25% with the exception of ka, partly attributable to the sparse
design, and ωCl/F as observed for the indinavir data. The VPC obtained with the basic model
parameters estimates is displayed in Figure 2b, together with the observed concentrations.
The results of the basic model evaluation were very satisfactory.
Effects of orosomucoid (P=0.03), albumin levels (P=0.04) and CYP3A5 polymorphism
(patients with 2 wild alleles at most vs other genotypes, P = 0.04) on Cl/F were found on the
individual parameters by use of non-parametric tests as well as effects of HIV disease status
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Fig. 2 Visual predictive check of the basic population PK model: comparison between the median (continued
line) and the 90th interval (colored area) predicted for 1000 simulated datasets and the observed concentra-
tions of indinavir (a) and of ritonavir (b). In the indinavir plot the open circles correspond to an indinavir dose
of 400 mg, the open triangles to 600 mg and the crosses to 800 mg
(P = 0.05) on ka and creatinine clearance (P = 0.1) on V/F. In the final model, an increase of
0.5 g/L in orosomucoid from the median (1 g/L) was associated with a clearance decrease
of 28% (P=0.03, LRT by permutation):
Cl/F = 8.3×Orosomucoid−0.8
The population parameters of this model and their RSE are given in Table 4.
3.4 Link between indinavir and ritonavir PK parameters
Four positive correlations between individual parameters of ritonavir and indinavir were
found significant. There was a relationship between indinavir and ritonavir absorption rate
constant (r = 0.4, P = 0.005). Indinavir clearance was strongly correlated to ritonavir clear-
ance (r = 0.6, P < 0.0001) and to a smaller degree to ritonavir volume of distribution (r = 0.4,
P < 0.01), while indinavir volume of distribution was highly correlated to ritonavir volume
of distribution (r = 0.5, P < 0.002).
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Fig. 3 Differences in log viral load (∆ logVL) observed between treatment initiation and week 2 versus area
under the concentration-time curve (a) and trough plasma concentration of indinavir (b) predicted by the
model
3.5 Concentrations link with short-term efficacy and safety
There was a significant decrease in viral load in the first two weeks of treatment and a
significant increase in total cholesterol, glycaemia and triglycerides in the first four weeks
of treatment, as shown in Table 5.
The decrease in log viral load was significantly associated with higher indinavir AUC
(r = -0.4, P = 0.03) and Ctrough (r = -0.4, P = 0.03), as shown in Figure 3. No significant
difference in viral load decrease was found between the five patients with a Ctrough below
the lower limit of the therapeutic range and the thirty five patients with a Ctrough above this
value.
Further, no significant relationship was found between indinavir nor ritonavir concen-
trations and safety measurements or grade 2 diarrhoea. No nephrolithiasis has been reported
in the COPHAR 2 - ANRS 111 trial, which has prevented us to analyze the link between
concentrations and this adverse event associated with indinavir.
The genetic covariate kept in the final population pharmacokinetic model was the CYP3A4*1B
polymorphism categorised in 2 classes: *1B*1B versus other genotypes. Both Cmax and
triglycerides increase were found to be significantly associated with the CYP3A4*1B poly-
morphism, althought not significantly correlated. In patients’ homozygotes for the *1B al-
lele, Cmax was significantly lower (median 3.6 [range 2.2 - 5.2] ng/mL compared with the
other groups 4.4 [2.2 - 8.3] ng/mL, P=0.04) and the increase in triglycerides was also sig-
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Fig. 4 Peak indinavir concentrations predicted by the model (a) and differences in triglycerides
(∆ triglyceride) 4 weeks before and after treatment initiation (b) versus CYP3A4 genotype. The solid-line
represents the median in each group
nificantly smaller (0.1 [-0.7 - 1.4] mmol/L versus 0.6 [-0.5 - 1.7] mmol/L, P=0.02), as illus-
trated by Figure 4. Regarding the efficacy, no significant association was found between the
CYP3A4*1B*1B genotype and the Ctrough or the log viral decrease.
The various doses of indinavir were not found to be associated with the CYP3A4*1B
polymorphism, short-term efficacy or safety, which dismissed its potential confounding ef-
fect.
4 Discussion
The pharmacokinetics of indinavir was analysed by use of a one compartment model with
first-order absorption and elimination at steady-state. The estimated clearance and volume
of distribution were 22.2 L/h and 97.3 L respectively, both in the range of those obtained
in previous studies [9,11,32]. In this study, the ABCB1 exon 26 and 21 and the CYP3A5*3
and *6 polymorphisms were not found to significantly influence the pharmacokinetics of
indinavir. Whereas, the absorption rate was 0.6 h−1 for CYP3A4*1B*1B patients and 2.1
h−1 for CYP3A4*1A*1A or CYP3A4*1A*1B patients. The CYP3A enzymes are distributed
in both hepatocytes and enterocytes [33] and their inhibition by ritonavir is well-documented
[34–36]. In vivo, the genotype-phenotype correlation for CYP3A4*1B remains a subject of
debate [37–40], however CYP3A4*1B has been related to increased transcription [41] in
in
se
rm
-0
03
84
93
5,
 v
er
sio
n 
1 
- 1
7 
M
ay
 2
00
9
12
vitro. We hypothesised that in CYP3A4*1B*1B patients the ritonavir inhibition potency is
lowered, which leads to higher first pass effect of indinavir although it does not impact on
its clearance. The potential confounding effect of the ethnic group has been discarded, as
this covariate was not significantly related to indinavir individual parameters in the sample.
Still, this finding is more relevant clinically in an african population given the extremely
low frequency of the CYP3A4*1B*1B genotype among caucasian. The primary objective of
the COPHAR2 study was not to assess the influence of genetic polymorphisms on indinavir
pharmacokinetics, and the use of modelling has helped to circumvent the limited sample size
of forty patients. In addition, most of the tests in this study were performed at an exploratory
step and final inclusion in the model was based on permutation to cope with departure from
the asymptotic assumption [30]. No evidence for a gender effect was found as reported
in some other studies on indinavir PK [9–11] but there were only thirteen women in the
present study. The dose was not found to influence the pharmacokinetics of indinavir and
using ritonavir as a boost hides dose non linearity of indinavir [42]. We did not assess the
impact of the diet, as these data were not available, but patients were recommended to ingest
the pills with food containing a sufficient amount of fats.
We also performed a population pharmacokinetic analysis of ritonavir concentrations.
Ritonavir profiles were adequately described by a one compartment model with first order
absorption and elimination processes, with estimates of the parameters in good agreement
with previous studies [6,43,44]. The estimated inter-individual variance for the absorption
constant was singularly large. We found a negative relationship between ritonavir clearance
and the orosomucoid level in plasma. The affinity of ritonavir for orosomucoid protein as
well as its impact on PI intracellular concentrations and efficacy has been described in both
in vitro and in vivo studies [45–47]. In patients with high orosomucoid plasma level, the
decrease in unbound fraction of ritonavir led to a lower clearance.
In the analysis of both protease inhibitors, the few concentrations (1.3% and 2% for
indinavir and ritonavir, respectively) below the limit of quantification were discarded. This
approach has been shown to provide using SAEM a less important bias than to set those to
LOQ/2 [48] and in MONOLIX 2.1, no proper method to handle LOQ was implemented.
In the analysis of the link between indinavir and ritonavir concentrations, we chose not
to include ritonavir as a covariate in the indinavir model, as performed in previous studies
[10,11]. Indeed, such parameterisation assumes unidirectional influence of ritonavir on in-
dinavir which is not true. Ritonavir concentrations when ritonavir is given with lopinavir
are lower than when ritonavir is given with indinavir [44]. We have instead underlined the
different levels of interaction between indinavir and ritonavir PK, especially at the absorp-
tion step, with the strong correlation between their absorption constant, but also in terms
of bioavailability as the oral clearances and volumes of distribution were highly correlated.
In order to properly model such an interaction between PI, a joint population analysis of
concentrations of indinavir and ritonavir should be considered with correlated absorption
constants and bioavailabilities.
We observed significant changes in viral load after two weeks of treatment and we con-
firmed the association between high indinavir trough and mean concentrations and a greater
decrease of viral load, which has already been described in PI naive patients [49–51]. We
did not find any relationship between CYP3A4*1B polymorphism and viral load decrease.
We also observed a significant increase, after four weeks of treatment, of total cholesterol,
glycaemia and triglycerides, as already reported [52], which was, however, not significantly
related to indinavir concentrations at week 2. Ritonavir was found in singularly high levels
in the study and is known to affect metabolic profiles, yet we have found no evidence of
an association between ritonavir levels and safety measurements. In patients’ homozygotes
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for the CYP3A4*1B allele, the ritonavir-decreased inhibition on indinavir metabolism led
to significantly lower indinavir Cmax and appeared to impact at a metabolic level trough a
significantly lower increase in triglycerides in these patients.
5 Conclusion
We developed and validated models for indinavir and ritonavir PK with reduced sampling
in indinavir HAART patients. Both the average and through concentrations were found to
be predictor of the viral load decline. Only the CYP3A4*1B allele was found to influence
indinavir absorption and biochemical safety, but no evidence was found of an impact of the
five genetic polymorphisms under study on indinavir efficacy.
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Table 1 Characteristics of the 40 studied patients
Median [Range]
Age (years) 36.5 [20.0 - 59.0]
BMI (kg/m2) 22.6 [17.5 - 35.8]
Weight (kg) 68.0 [45.0 - 103.0)
Creatinine clearance (mmol/L) 95.4 [57.4 - 245.1]
Albumin (g/L) 38.4 [25.5 - 47.4)
Orosomucoid (g/L) 1.0 [0.5 - 2.9]
Number of patients (%)
Dose (400/600/800mg) 26 (65) / 8 (20) / 6 (15)
Coadministration of AZT/3TC (y/n) 33 (83) / 7 (17)
Coinfection VHB/VHC (y/n)∗ 7 (18) / 32 (82)
Good adherence (y/n) 15 (38) / 25 (62)
Sex (male/female) 27 (68) / 13 (32)
Ethnic group (African/Caucasian) 20 (50) / 20 (50)
CDC classification for HIV infection (A or B/C) 30 (75) / 10 (25)
∗ One patient had this information missing
Table 2 Distribution of the genetic polymorphisms within each ethnic group and P-values for the Hardy-
Weinberg proportions test (H-W)
Number of patients (%) H-W P-value
African
ABCB1 exon 26 (CC/CT/TT) 11 (55) / 9 (45) / 0 (0) 0.43
ABCB1 exon 21 (GG/GT/TT) 19 (95) / 1 (5) / 0 (0) 0.99
CYP3A5 (4 *1/3 *1/≤2 *1) 0 (0) / 8 (40) / 12 (60) 0.53
CYP3A4*1B (*1A*1A/*1A*1B/*1B*1B) 9 (45) / 8 (40) / 3 (15) 0.86
Caucasian
ABCB1 exon 26 (CC/CT/TT) 2 (12) / 12 (70) / 3 (18) 0.22
ABCB1 exon 21 (GG/GT/TT) 4 (21) / 11 (58) / 4 (21) 0.79
CYP3A5 (4 *1/3 *1/≤2 *1) 18 (100) / 0 (0) / 0 (0) 1
CYP3A4*1B (*1A*1A/*1A*1B/*1B*1B) 0 (0) / 3 (16) / 16 (84) 0.93
Note : One patient had missing information for all genotypes, ABCB1 exon 26 and
CYP3A4 genotypes were also both missing in another patient, in addition one
patient had missing genotype for ABCB1 exon 26
Table 3 Population pharmacokinetic parameters of indinavir for the basic and the final model: estimates and
relative standard error (RSE)
Basic model (N = 40) Covariate model (N = 38)
Parameters Estimates RSE (%) Estimates RSE (%)
ka(h−1) 1.3 33.7 2.1 44.1
βCY P3A4ka - - -1.3 42.0
Cl/F (L/h) 21.9 6.9 22.2 6.9
V/F (L) 93.9 8.2 97.3 9.3
ωka (%) 118.0 22.9 98.2 28.7
ωCl/F (%) 34.4 15.0 34.9 15.0
ωV/F (%) 19.3 66.8 21.6 57.8
σ (%) 44.5 8.9 44.7 8.6
RSE = relative standard error
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Table 4 Population pharmacokinetic parameters of ritonavir for the basic and the final model: estimates and
relative standard error (RSE)
Basic model (N = 39) Covariate model (N = 39)
Parameters Estimates RSE (%) Estimates RSE (%)
ka(h−1) 2.4 98.7 2.2 93.5
Cl/F (L/h) 8.7 9.4 8.3 9.0
β OrosomucoidCl - - -0.8 46.5
V/F (L) 61.6 8.6 60.7 8.7
ωka (%) 357.7 21.9 346.8 21.5
ωCl/F (%) 55.9 12.2 52.4 12.4
ωV/F (%) 22.8 53.9 23.3 51.5
σ (%) 30.4 8.4 30.3 8.4
RSE = relative standard error
Table 5 Median [range] of the studied short-term efficacy and safety measurements and of the change from
baseline
Baselinea W2 or W4b Difference from
baseline
P-value
Efficacy
Log viral load (log copies/mL) 4.9 [3.4 - 6.3] 2.9 [1.8 - 4.1] -1.8 [-2.8 - -0.5] <0.001
Safety
Total cholesterol (mmol/L) 4.3 [1.9 - 7.4] 5.0 [2.9 - 7.5] 0.8 [0.8 - 4.7] <0.001
HDL cholesterol (mmol/L) 1.1 [0.5 - 1.8] 1.1 [0.4 -2.1] 0.1 [- 0.7 - 1.0] 0.09
Glycaemia (mmol/L) 4.7 [3.4 - 6.0] 4.9 [2.8 - 7.1] 0.2 [-1.0 - 2.7] 0.013
Triglycerides (mmol/L) 1.0 [0.4 - 3.0] 1.4 [0.6 - 4.0] 0.4 [-0.7 - 1.7] <0.001
Creatinine clearance (mL/min) 98.4 [62.0 - 195.7] 97.4 [62.8 - 252.0] -1.0 [-38.0 - 56.4] 0.5
a Baseline = D0 for log viral load and W-4 for safety
b W2 for log viral load and W4 for safety
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